Key Highlights:
- Schrödinger, Inc. (SDGR, Financial) unveils promising preclinical data at AACR 2025.
- Analyst price targets indicate a potential 60.25% upside.
- GF Value suggests a 93.6% upside from current levels.
Schrödinger's Latest Breakthroughs
Schrödinger, Inc. (SDGR) is gearing up to present groundbreaking preclinical findings related to its cancer inhibitors, SGR-3515 and SGR-4174, at the esteemed AACR Annual Meeting 2025. Recent data reveal that SGR-3515 showcases a promising therapeutic profile, paving the way for further trials in advanced tumors. Additionally, SGR-4174 is emerging as a potential game-changer in targeting KRAS-driven cancers, capturing the attention of the oncology community.
Wall Street Analysts Forecast
Current analysis from 10 Wall Street experts places the one-year price target for Schrödinger Inc (SDGR, Financial) at an average of $30.80. This includes a high projection of $39.00 and a low estimate of $26.00. The average target suggests an impressive upside of 60.25% from the existing price of $19.22. For a more in-depth exploration of these estimates, visit the Schrodinger Inc (SDGR) Forecast page.
Brokerage Recommendations & GF Value
According to the consensus across 10 brokerage firms, Schrödinger Inc's (SDGR, Financial) average recommendation is 2.0, reflecting an "Outperform" status. This rating scale ranges from 1 to 5, with 1 indicating a Strong Buy and 5 representing a Sell.
GuruFocus projects an estimated GF Value of $37.21 for Schrödinger Inc (SDGR, Financial) in the upcoming year. This implies a upside of 93.6% from the current price of $19.22. GF Value represents GuruFocus's fair value estimation, derived from the stock's historical trading multiples, its past business growth, and future performance projections. For more comprehensive data, refer to the Schrodinger Inc (SDGR) Summary page.
